Tuesday, November 2, 2010

Afinitor receives FDA approval for a new indication (now approved to treat rare genetic disorder)

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

You can read more here.

No comments:

Post a Comment